Printer Friendly

BREAKTHROUGH TREATMENT FOR HUMAN PAPILLOMA VIRUS COMES FROM RUSSIAN RESEARCH

 ARLINGTON, Va., Nov. 22 /PRNewswire/ -- A new discovery by Russian researchers for the treatment of human papilloma virus (HPV) may offer relief to tens of millions of people who suffer discomfort from the disease. HPV is the common name for a group of related viruses, some of which cause genital warts. The disease has spread so rapidly that it is now one of the most common sexually transmitted diseases in the world.
 Medical researchers have been gathering experimental data on the human papilloma virus for some time and have found a strong correlation between many malignancies and papillomatoses. The Russian breakthrough offers an effective treatment without pain and suffering. The research information and the formula for the medication are being marketed to international pharmaceutical companies by East/West Technology Partners Ltd. of Arlington.
 Over the last 15 years in the United States alone, the Center for Disease Control reports a 400 percent increase in the number of visits to private doctors for HPV cases. HPV is found in more than 12 million Americans with an estimate of at least 1 million new cases diagnosed each year. A pamphlet published by the American College of Obstetricians and Gynecologists mentions that beginning in the early 1980s, "doctor visits for genital warts outnumbered visits for genital herpes by three to one." Certain types of HPV lesions have been linked to changes in cervical tissue that could become cancerous if left untreated. HPV is most often reported in women, but increasing numbers of men are being diagnosed with HPV lesions with a corresponding increase in reported cases of penile cancer.
 Although HPV is now more common than herpes, less is understood about whether or not the disease is transmitted only when lesions or warts are apparent or whether it can be transmitted by symptom-free carriers. The warts and lesions can appear two to three months after infection and can reoccur even after surgical removal or chemical treatment. The disease can manifest itself as hard, fleshy bumps, reddish or pink dots or as a cluster that looks like tiny cauliflowers. When they occur inside the vagina or the cervix, self-diagnosis is difficult. The warts are extremely unpleasant and can cause irritation, itching and bleeding. The symptoms will usually go away after several days or weeks, even without treatment. Nevertheless, medical research indicates that it is prudent to remove HPV-related lesions and to be diligent in conducting frequent Pap smears in women with a history of genital warts. Treatment is especially important for pregnant women because active infections present during delivery can endanger the newborn. As discomforting as the HPV lesions and warts are, current treatments are also unpleasant and can be dangerous.
 In the United States, HPV is most often treated in a doctor's office with or without local anesthetic. Methods of treatment involve one or more of the following: cold cautery -- destroying the warts by freezing, a treatment similar to removing common warts on the hands or feet; hot cautery -- burning the warts off with an electrical instrument; laser treatment -- using a pinpoint laser light beam to burn the wart (laser surgery to the vagina is difficult and may not be successful); surgery for removal of warts, which produces scars; and treatment with chemical solutions such as Podophyllin and trichloroacetic acid, powerful drugs that destroy genital warts. These drugs may cause burning and must be used very carefully by a doctor so as not to harm healthy skin. Podophyllin cannot be used on pregnant women. Use of 5-fluorouracil (5-FU) cream, more commonly used as a chemotherapy dermo-abrasive treatment, has been frequently prescribed, but more and more doctors are abandoning it because it is extremely caustic and may have troublesome side effects. More serious infections are treated in a hospital operating room under general anesthesia.
 The Russian treatment involves a formula for a dilute topical solution, that when applied daily for up to two weeks, causes condylomas, flat and common warts to disappear. Unlike current non- surgical HPV treatments, tests have found no side effects from the medication such as pain, itching, burning, erythema, etc. The treatment drug, which contains Papirines, is inexpensive to manufacture, soluble in water and stable in a liquid sterile aqueous solution at room temperature or in frozen or lyophilized state for many months. Papirines are the known synthetic analogs of a natural component of animal cells.
 East/West Technology Partners, Ltd., is a joint venture of one Russian and two American companies. Made up of BDM International, Inc., of McLean, Va.; INTEX Corporation of Washington and a Russian joint stock company known as Technology Exhibition & Investment, Inc. (TEI), of Moscow, the company was established to be a source for a wide variety of advanced technologies developed in the former Soviet Union. East/West Technology identifies, evaluates and assesses technologies that have application to businesses and industries in the West. The corporation acquires, licenses, patents and handles all title and technology transfer issues.
 The Russian partner is owned and staffed by prominent academicians, scientists and engineers in a wide range of fields from hundreds of universities and institutes in the former Soviet Union. The company has received the endorsement of the Russian Academy of Sciences. Under the terms of the joint venture, the Russian inventors share equally in the licensing revenues generated.
 -0- 11/22/93
 /CONTACT: Dr. Mark S. Taylor of East/West Technology Partners, 703-351-6910, or fax, 703-351-6909/


CO: East/West Technology Partners, Ltd. ST: Virginia IN: MTC SU:

MH-IH -- DC011 -- 6820 11/22/93 12:55 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1993
Words:919
Previous Article:BABBITT SETTLEMENT
Next Article:FIRST FINANCIAL CORPORATION OF WESTERN MARYLAND DECLARES DIVIDEND
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters